RxDoctor Payments Data

Michael Taylor, MD

Urology · Meridian, IDNPI 1689828162

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $2,152 of the $3,190 with a category attached, or 67.5%. Boston Scientific accounts for 82.8% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2022 at $2,353 and has fallen 86.4% since, to $320 in 2025. That places this record below the midpoint for urology clinicians in ID, where the typical reported total is $3,075.

$3,190in general payments, 2019–2025

Across 49 payments — averaging $65.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Astellas Pharma US Inc$116
  • Procept Biorobotics Corporation$101
  • Urogen Pharma, Inc.$61
  • AbbVie$47
  • Ferring Pharmaceuticals Inc.$41
  • plus $181 from 9 others

What the payments were for

  • Travel & lodging$2,15267%
  • Food & beverage$1,02732%
  • Education$110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,190 in reported general payments places this provider in the 50th percentile of 55 urology providers in Idaho.

See all urology providers in Idaho

Medicare billing

Part B allowed, 2024
$155,936
Medicare patients
471
Services billed
1,836

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron187$149,581
GemtesaVibegron20$25,014
Tamsulosin Hcl677$7,594
Trospium Chloride ErTrospium Chloride54$6,986
Tolterodine Tartrate ErTolterodine Tartrate37$5,587
Silodosin39$5,255
Potassium Citrate ErPotassium Citrate37$4,596
Oxybutynin Chloride ErOxybutynin Chloride134$4,009
Testosterone36$3,968
Testosterone Cypionate67$3,776
Finasteride242$3,252
Alfuzosin Hcl ErAlfuzosin Hcl54$1,479
Dutasteride24$1,364
Oxybutynin Chloride75$1,141
Trimethoprim15$1,083

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$116$149,581187 claims
Sumitomo Pharma America, Inc.Gemtesa$27$25,01420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 55 urology providers in Idaho.

Other urology in Meridian

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →